secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001601830-25-000034
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion reports Q4 net loss $178.9M, FY2024 net loss $463.7M; cash runway into 2027
--------------------------------------------------------------------------------

- Cash, cash equivalents and restricted cash $603.0M at Dec 31, 2024 vs $401.4M at Dec 31, 2023; runway extended into 2027.
- Q4 revenue $4.5M (down 59% YoY); FY2024 revenue $58.8M (up 32% YoY). Pro forma revenue $82.6M.
- Operating cash outflow $115.4M in Q4; $359.2M for FY2024. Exscientia cash burn ~$184M pre-acquisition.
- Completed Exscientia merger Nov 2024; maintaining guidance of at least $100M in annual synergies.
- Pipeline advanced: REC-617 showed durable partial response; three new clinical trials initiated (DAHLIA, TUPELO, ALDER).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000034/0001601830-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000034/rxrx-20250228.htm
  HTML page:      https://secwatch.observer/filing/0001601830-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer